company background image
SWTX logo

SpringWorks Therapeutics NasdaqGS:SWTX Stock Report

Last Price

US$38.30

Market Cap

US$2.9b

7D

-7.8%

1Y

12.7%

Updated

13 Dec, 2024

Data

Company Financials +

SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stock Report

Market Cap: US$2.9b

SWTX Stock Overview

A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. More details

SWTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for SWTX from our risk checks.

SpringWorks Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SpringWorks Therapeutics
Historical stock prices
Current Share PriceUS$38.30
52 Week HighUS$53.92
52 Week LowUS$28.21
Beta0.79
1 Month Change10.34%
3 Month Change2.35%
1 Year Change12.68%
3 Year Change-45.43%
5 Year Change5.36%
Change since IPO69.24%

Recent News & Updates

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

Nov 15
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

Recent updates

Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

Nov 15
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results

SpringWorks Therapeutics Merits A Speculative Buy

Nov 04

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

Aug 07

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07
We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SpringWorks drops 21% as Allogene drops lead asset in combination study

Aug 10

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Aug 04

Sizing Up SpringWorks Therapeutics

Jul 20

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06
Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

May 02

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Shareholder Returns

SWTXUS BiotechsUS Market
7D-7.8%-2.7%-0.4%
1Y12.7%3.3%27.7%

Return vs Industry: SWTX exceeded the US Biotechs industry which returned 3.3% over the past year.

Return vs Market: SWTX underperformed the US Market which returned 27.7% over the past year.

Price Volatility

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement6.2%
Biotechs Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: SWTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SWTX's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017305Saqib Islamwww.springworkstx.com

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.

SpringWorks Therapeutics, Inc. Fundamentals Summary

How do SpringWorks Therapeutics's earnings and revenue compare to its market cap?
SWTX fundamental statistics
Market capUS$2.88b
Earnings (TTM)-US$275.16m
Revenue (TTM)US$135.49m

21.0x

P/S Ratio

-10.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SWTX income statement (TTM)
RevenueUS$135.49m
Cost of RevenueUS$7.42m
Gross ProfitUS$128.07m
Other ExpensesUS$403.23m
Earnings-US$275.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.70
Gross Margin94.52%
Net Profit Margin-203.09%
Debt/Equity Ratio0%

How did SWTX perform over the long term?

See historical performance and comparison